The information highlighted (if any) are the most recent updates for this brand.
Buventol Easyhaler is an inhalation powder packed into a multiple dose powder inhaler from which the patient can accurately deliver the individual drug doses. It is for oral inhalation.
Buventol Easyhaler 200 mcg/dose Inhalation Powder: The product contains salbutamol sulphate equivalent to 200 mcg of salbutamol per metered dose. The dose, which the patient gets through the mouthpiece of the device is 180 mcg of salbutamol.
The Buventol Easyhaler multiple dose powder inhaler contains 200 doses of finely powdered salbutamol sulphate mixed in a small quantity of lactose. The amount of drug received by the patient (180 mcg/dose) corresponds to that from salbutamol inhalation aerosol. The dose to be inhaled is released from the container by pressing the device between the thumb and forefinger. This is followed by inhalation through the device. As a result, salbutamol particles are transferred to their target, the lungs. Use of the Buventol Easyhaler does not require coordination of actuation of the dose and inhalation.
Excipients/Inactive Ingredients: Lactose monohydrate (contains milk protein).
Pharmacotherapeutic group: Selective beta2-adrenoreceptor agonists. ATC code: R03AC02.
PHARMACOLOGY: Pharmacodynamics: The pharmacologic effects of salbutamol are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle. Bronchial effects of inhaled salbutamol can be detected after few minutes and duration of action is normally 4-6 hours.
Like other beta2-adrenoceptor agonists also salbutamol has cardiovascular effects in some patients as measured by changes in pulse rate, blood pressure, symptoms and ECG changes. These effects can especially be detected after oral and intravenous administration of salbutamol. In addition, salbutamol has some metabolic effects. Especially intravenous and nebulized salbutamol decreases serum potassium concentrations although the effect is generally mild and transient.
Pharmacokinetics: After administration of salbutamol by the inhaled route between 10 and 25% of the dose reaches the lung. The remainder is retained in the delivery system or is deposited in the oropharynx from where it is swallowed. The fraction deposited in the airways is absorbed into the pulmonary tissues and circulation, but is not metabolised by the lung. On reaching the systemic circulation it becomes accessible to hepatic metabolism and is excreted primarily in the urine. The swallowed portion of an inhaled dose is absorbed from the gastrointestinal tract and undergoes considerable first-pass metabolism. Both unchanged drug and conjugate are excreted primarily in the urine. The elimination half-life of salbutamol is 2.7 to 5.5 hours after oral and inhaled administration.
Toxicology: Preclinical safety data: Acute toxicity of salbutamol is low in the mouse, rat and dog. LD50 values in these species have exceeded several thousand fold the intended human therapeutic doses. Reported findings in repeated dose studies such as tachycardia, increases in heart weights and hypertrophy of muscle fibres are common to all potent selective beta2-agonists and are an expression of excessive beta-stimulant action. Cleft palate has been reported in mice but not in rats or rabbits after subcutaneous administration. Salbutamol is not mutagenic. Mesovarian leiomyomas, benign tumours of smooth muscle, occur particularly in Sprague-Dawley rats, but not in other species.
Symptomatic treatment of acute asthma attack.
Prevention of exercise-induced bronchospasm.
Symptomatic treatment of bronchial asthma and other conditions, such as bronchitis and emphysema, associated with reversible airways obstruction.
The preparation is intended for oral inhalation only. This preparation is particularly useful for patients who are unable to use metered dose inhaler properly and for patients to whom the use of inhalation aerosol causes irritation of airways. The lowest effective doses of inhaled salbutamol are recommended and instead of regular use it is recommended to use inhaled salbutamol when needed.
Adults: For the relief of acute asthma or before exercise 100 - 400 mcg. The recommended dose for maintenance treatment or prophylactic therapy is 100 - 400 mcg two to four times a day. Maximum dose is 2.4 mg / day.
Children: In the treatment of episodic asthma or before exercise 100 - 200 mcg. The recommended dose for maintenance or prophylactic treatment is 100 - 200 mcg two to four times daily. Maximum dose is 1.2 mg / day.
Instruction for use/handling: Patients have to be instructed to perform a strong and deep inhalation through the Easyhaler device. Patients have to be instructed not to exhale into the device.
Excess repeat use of inhalations may produce adverse effects such as tachycardia, CNS stimulation, tremor, hypokalaemia and hyperglycaemia.
Treatment consists of discontinuation of salbutamol Easyhaler together with appropriate symptomatic therapy. If hypokalaemia occurs potassium replacement via oral route should be given. In patients with severe hypokalaemia intravenous replacement may be necessary.
Known hypersensitivity to salbutamol or to milk proteins (the excipient lactose contains milk proteins).
Rapidly increasing use of short-acting inhaled beta2-agonists to relieve symptoms, indicates deterioration of asthma control (especially if peak expiratory flow rate value falls and/or becomes irregular). Patients should therefore be advised that in these cases the doctor's advice should be obtained as soon as possible, and therapeutic management should then be reassessed.
A regular anti-inflammatory controller medication taken on a daily basis is required, as soon as the patient needs inhaled beta2-agonists more than twice a week.
Salbutamol should be given with caution in patients suffering from thyrotoxicosis, cardiac insufficiency, hypokalaemia, myocardial ischemia, tachyarrhythmia and hypertrophic obstructive cardiomyopathy.
Potassium levels should be monitored in severe asthma as hypokalaemia potentially caused by salbutamol may be potentiated by concomitant treatment and by hypoxia (see Interactions).
Rarely inhalation therapy may cause bronchospasm after dosing. In this event, treatment with Salbutamol Easyhaler must be immediately discontinued and, if need be, replaced with another therapy.
Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol. Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin.
One dose contains less than 10 mg lactose, which probably does not cause symptoms in lactose intolerant patients. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Effects on ability to drive and use machines: The effect of Salbutamol Easyhaler on the ability to drive and use machines has not been directly studied. From the well-known pharmacological actions of salbutamol and decades of clinical experience such effects are, however, regarded as unlikely.
Pregnancy: Administration of salbutamol during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
Lactation: As salbutamol is excreted in breast milk its use in nursing mothers requires careful consideration. As it is not known whether salbutamol has harmful effects on the neonate, its use should be restricted to situations where it is felt that the expected benefit to the mother is likely to outweigh any potential risk to the neonate.
The undesirable effects caused by normally used inhaled doses of salbutamol are mild, typical for sympathomimetic agents, and they usually disappear with continued treatment.
The most common adverse effects of salbutamol include peripheral vasodilatation and as a result small increase in heart rate, palpitations and tremor. Other adverse effects of salbutamol include headache, hypersensitivity reactions (angioedema, urticaria, hypotension and collapse), bronchospasm (see Precautions), cough, irritation of mouth and throat which may be prevented by rinsing the mouth after inhalation, hypokalaemia, muscle cramps, hyperactivity, restlessness, dizziness and cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia and extrasystoles, myocardial ischaemia (see Precautions).
If additional adrenergic drugs are administered to patients using Salbutamol Easyhaler they should be used with caution to avoid deleterious cardiovascular effects. Patients treated with monoamine oxidase inhibitors or tricyclic antidepressants should be followed clinically in the beginning of salbutamol treatment, because the action of salbutamol on the vascular system may be potentiated. Beta-blockers, such as propranolol, inhibit the effect of salbutamol like that of any other beta2-agonists.
The simultaneous administration of xanthines, corticosteroids or potassium excreting diuretics may increase hypokalaemia.
Incompatibilities: Not applicable.
Store in a dry place, not exceeding 25°C.
Shelf-life: 3 years when stored in laminated pouch, 6 months after opening of the pouch.
R03AC02 - salbutamol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Buventol Easyhaler powd for inhalation 200 mcg/dose
((200 doses)) 1's